Gonorrhea Diagnostic Market Analysis Till 2027 - New Study By Coherent Market Insights

Gonorrhea is a sexually transmitted disease caused by a bacterium Neisseria Gonorrhoeae. It is one of the most common sexually transmitted diseases and affects millions of people each year. According to the study, ‘Global epidemiology of Neisseria gonorrhoeae in infertile populations: systematic review, meta-analysis and metaregression’, published in BMJ Journals in May 2020, the pooled mean prevalence of current gonorrhoea infection worldwide was at 2.2%, with the highest prevalence in Africa at 5.0%. Thus, high prevalence of gonorrhea in emerging economies is expected to propel growth of the gonorrhea diagnostic market.

Request PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/126

Diagnostic tools available in the gonorrhea diagnostic market include urine test, swab test and nucleic acid amplification testing (NAAT). The gonorrhea diagnostic market is witnessing R&D of new approaches for diagnosis. In May 2021, researchers from Johns Hopkins University reported development of PROMPT (portable, rapid, on-cartridge, magnetofluidic purification and testing platform), an inexpensive portable device and a complimenting smartphone app that can diagnose gonorrhea infection in under 15 minutes. The study was published in Science Translational Medicine.

Emergence of Covid-19 has led to significant rise in sexually transmitted diseases, which is also expected to aid in growth of the gonorrhea diagnostic market. In November 2020, a study conducted in two main STI centers in Milan, Italy, revealed that diagnosis of STIs, including gonorrhea, secondary syphilis and mycoplasma genitalium (MG) has increased despite the lockdown restrictions. The study results were presented at the 29th European Academy of Dermatology and Venereology virtual conference.

Players in the gonorrhea diagnostic market are focused on expanding their distribution channel. In February 2021, Binx Health, a provider of point-of-care diagnostic solutions, partnered with McKesson, a healthcare company, for the sale and distribution of the Binx io molecular diagnostic testing platform in the US. The point-of-care platform enables the diagnosis and subsequent treatment of chlamydia and gonorrhea to take place in a single visit. Later, in April 2021, the Food and Drug Administration granted a CLIA waiver for the binx health io CT/NG assay, thereby allowing the use of the binx health io CT/NG assay at point-of-care settings.

Purchase Report at: https://www.coherentmarketinsights.com/promo/buynow/126

The gonorrhea diagnostic market in North America is expected to witness significant growth with surge in cases of gonorrhea infections. According to a Michigan Department of Health and Human Services press release, in Michigan reported a 22% increase in reported gonorrhea infections for 2020 compared to 18,264 gonorrhea infections in 2019.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.